Bestqool Honors Workers With Light-Based Recovery Solutions This Labor Day

From Aug 27 through Sep 4, all Bestqool Products will be available at unbeatable prices.

NEW YORK, Aug. 27, 2025 /PRNewswire/ -- After long hours of daily work, the body needs more than rest — it requires a sustainable, gentle, and easy-to-maintain recovery method. Bestqool, a health and wellness technology brand for light-based recovery, is celebrating this year's Labor Day with an important message: Honor your labor by protecting the body that does the work.

For a limited time, Bestqool is offering 12% off all products from August 27th to September 4th, giving workers the opportunity to bring red light therapy home and make recovery a part of their daily routine.

The Health Challenges Facing Workers — A Lopsided House

Today's labor force, whether it's in an office or on a construction site, is exposed to constant and multiple muscle strains. From office cubicles to construction sites, today's workers grapple with layers of stress. People working at desks all day commonly have stiff necks and shoulders, lower back pain, and strained eyes from prolonged sitting and screen time. Repeated movements and uncomfortable postures affect mainly the back, knees, wrists, and shoulders areas and put workers at risk of muscle and joint wear and tear over time.

Mental fatigue is equally widespread. High levels of mental strain have left office workers battling with headaches, lack of concentration, and disturbed sleep. Physically demanding jobs in loud, stressful conditions often drain physical and mental energy and reduce the ability to recover. These issues don't just disappear with a mini vacation or work pause; instead, they mount up, turning into chronic issues that steadily damage health and quality of life.

The Shortcomings of Conventional Treatments

For decades workers rely on various traditional pain relieving drugs and rehabilitation methods. They are effective, but each has its drawbacks.

• Medications: Pain killers and anti-inflammatories can ease symptoms temporarily, but their long term usage carries risk for the digestive system, kidneys and cardiovascular health.
• Physical therapy: Rehabilitation methods are effective but challenging as these require fixed appointments and travel during work hours, and financial commitment.
• Surgery/Interventional Procedures: While sometimes necessary and effective, these pose a higher risk and longer periods of recovery that many workers cannot afford.
• Heat/Cold therapy or Passive Rest: Treats only superficial symptoms but rarely fixes stiffness, fatigue, or deep tissue issues.

The Advantages of Light-Based Therapy (Photobiomodulation)

Red and near-infrared light therapy, commonly referred to as "red light therapy" (RLT), has been proven as a safe, effective, and sustainable pathway to recovery for today's workforce^[1][2][3]. In contrast to some other solutions that provide only temporary masking of symptoms, RLT works at the cellular level - supporting the body's recovery ability.^[4]

This form of therapy relies on specific wavelengths of light, specifically red (660 nm) and near-infrared (850 nm). They can pass through the skin and subcutaneous tissues, promoting circulation, improving the delivery of oxygen to the tissues, and facilitating energy production in the mitochondria of the cells^[4]. By promoting better cellular function, RLT helps the body heal itself effectively.

For an office professional managing tension in the neck and shoulders, or a frontline worker hampered with aching knees and painful back, RLT provides a soft but mighty approach to building resilience and quality of life over time. As compared to traditional treatments, light-based therapies have three distinct advantages:

Bestqool Products Recommendations For Workers

Bestqool devices are designed by keeping the needs of working people in mind — safe for frequent use, easy to operate, and beneficial for cumulative benefits. Three leading models will be highlighted in this year's Labor Day event.

BQ60 — Compact, Portable Dual-Wavelength Device

Combines 660nm red light (skin health, collagen, superficial recovery) with 850nm near-infrared light (deep tissue, joints and muscle recovery).

• Small and lightweight, it comes with a foldable stand, making it convenient.
• Ideal for local treatments such as neck, joints and shoulders after daily wear and tear.

Key Benefit: Portable and affordable without sacrificing medical-grade irradiance.

Pro100 — Mid-Size, Four-Wavelength Device

Delivers a higher irradiance output and larger treatment area compared with the BQ60.

• Combines four-wavelength for a broader range of benefits such as anti-aging, skin rejuvenation, muscle performance and deeper tissues recovery.
• Designed for Modular Use: Can be connected with additional panels for expanded coverage.

Key Benefit: Efficient for workers who desire both beauty/wellness benefits (skin, hair, mood) and deeper musculoskeletal recovery

Pro300 — Full-Surface, Four-Wavelength Device

Larger surface area for comprehensive body treatment; 2 units can be combined together for full body treatment.

• It emits stronger power density meaning shorter therapy sessions are needed to achieve therapeutic effect.
• Includes optional splicing hardware for modular expansion and ceiling, or stand mounting options for workplace or gym.

Key benefit: Superior efficiency and coverage - perfect for physically demanding workers, athletes, or anyone managing chronic conditions.

A Labor Day Commitment to Worker Wellness 

Labor Day should not be just a holiday; it is a reminder that the working class is the backbone of our society. While workers strive for a better life, they must also protect the body that makes the life possible. Bestqool's Labor Day sale isn't just about a discount — it's a tangible opportunity to add recovery into the regular routine.

Promotion Period: August 27th – September 4^th
Deal: 12% discount on all products of Bestqool
Available on both Bestqool official website and Amazon store

Schedule Caring for Yourself

For the millions of workers hustling their bodies for a chance at a better life, recovery should not be a luxury. Bestqool offers affordable, science-based tools to help people take care of themselves every day, building resilience not only for work, but for the moments that matter beyond it.

Bestqool hopes its easy-to-use, sustainable light-therapy devices will help make "recovery" an achievable daily habit. Prioritize self-care as part of your routine; small, regular investments in recovery compound into better work performance and higher quality of life.

Media contact

Name: Giselle
Email: marketing@bestqool.com

Reference list

1.Barolet, D., & Boucher, A. (2008). Prophylactic low-level light therapy for the treatment of hypertrophic scars and keloids: A case series. Lasers in Surgery and Medicine, 40(7), 441–450. https://doi.org/10.1002/lsm.20646

2. Gupta, A., Avci, P., Sadasivam, M., Chandran, R., Parizotto, N. A., Vecchio, D., ... & Hamblin, M. R. (2013). Shining light on the head: Photobiomodulation for brain disorders. Lasers in Surgery and Medicine, 45(7), 515–532. https://doi.org/10.1002/lsm.22190

3. Hamblin, M. R. (2017). Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophysics, 4(3), 337–361. https://doi.org/10.3934/biophy.2017.3.337

4. Huang, Y. Y., Chen, A. C., Carroll, J. D., & Hamblin, M. R. (2009). Biphasic dose response in low level light therapy. Dose-Response, 7(4), 358–383. https://doi.org/10.2203/dose-response.09-027.Hamblin

5. Schiffer, F., Johnston, A. L., Ravichandran, C., Polcari, A., Teicher, M. H., Webb, R. H., & Hamblin, M. R. (2009). Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: A pilot study of 10 patients with major depression and anxiety. Behavioral and Brain Functions, 5(1), 46. https://doi.org/10.1186/1744-9081-5-46

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Bestqool Honors Workers With Light-Based Recovery Solutions This Labor Day

HIGHLIGHTS

• Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol.

Patient population

• With the SECuRE trial continuing to recruit, a total of nine participants who had evaluable data by the 25^th of November 2025 were included in the interim assessment by the SRC, with the majority of participants receiving at least two cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each by the data cut-off date.
• Seven participants received ⁶⁷Cu-SAR-bisPSMA and two participants were treated with a combination of ⁶⁷Cu-SAR-bisPSMA with enzalutamide.
• Most participants were heavily pre-treated (with 55.6% having received more than 5 previous anti-cancer regimens) and had bone metastasis (66.7%).

Safety

• The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable with most related adverse events (AEs) in the Cohort Expansion to date being Grade 1 or 2. The most common AEs were nausea and lymphopenia (observed in 33.3% of participants, for each AE).

Efficacy

• Six participants had at least two prostate specific antigen (PSA) results following ⁶⁷Cu-SAR-bisPSMA administration, with all showing a decrease in PSA. Of those, four participants (66.7%) thus far had a reduction of more than 50% in PSA (PSA50) and two participants (33.3%) had a reduction of more than 80% (PSA80).
• One participant who presented with bone metastasis at enrolment achieved undetectable PSA with no prostate cancer detected by computed tomography (CT) or bone scan following ⁶⁷Cu-SAR-bisPSMA treatment. The participant reported having excellent quality of life following the treatment.

Next Steps

• The SECuRE trial will continue enrolment into the Cohort Expansion Phase with planned completion of recruitment in 2026. Phase III registrational trial planning ongoing based on data generated to date.

SYDNEY, Jan. 15, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to share a number of updates on the SECuRE trial following an SRC meeting. The SRC has recommended that the trial continue with the Cohort Expansion Phase (Phase II) as planned with no modifications to the protocol. The interim results assessed by the SRC were collected from nine participants enrolled in the cohort that had evaluable data by the cut-off date of the 25^th of November 2025 and continue to show promising efficacy and a favourable safety profile of ⁶⁷Cu-SAR-bisPSMA.

The majority of the nine participants had bone metastasis at enrolment (66.7%) and received multiple lines of previous treatments (more than 5 previous anti-cancer regimens, 55.6%). Median PSA prior to ⁶⁷Cu-SAR-bisPSMA treatment was 18.9 ng/mL (range 1.5-30.2 ng/mL). Six out of these nine participants received at least 2 cycles of 8 GBq of ⁶⁷Cu-SAR-bisPSMA each, with two of them also receiving concomitant enzalutamide.

Of the nine participants included in this SRC analysis, six had at least two PSA results following their ⁶⁷Cu-SAR-bisPSMA treatment by the data cut-off date. Of these six participants, thus far four (66.7%) showed reductions in PSA of 50% or more (PSA50) and two (33.3%) showed reductions of 80% or more (PSA80).

The safety profile of ⁶⁷Cu-SAR-bisPSMA remains favourable in the Cohort Expansion, with the majority of related AEs being Grade 1 or 2. The most common related AEs were nausea and lymphopenia (observed in three out of nine participants [33.3%], for each AE). The only AE that was Grade 3 or above was lymphopenia observed in three participants, some of whom had bone metastasis at baseline and/or had received multiple lines of therapy, including taxane and an investigational agent, prior to enrolment in the SECuRE study. There have been no overall renal toxicity or electrocardiogram (ECG) changes observed in these participants. In the combination enzalutamide arm, no new AEs (or worsening of AEs) related to ⁶⁷Cu-SAR-bisPSMA have been observed to date.

Trial participant with no detectable disease after 3 cycles of ⁶⁷Cu-SAR-bisPSMA

One of the participants in the Cohort Expansion was a 64-year-old man with bone metastases and baseline PSA of 5.4 ng/mL prior to entering the SECuRE study. Following his first cycle of ⁶⁷Cu-SAR-bisPSMA, this participant showed a dramatic 95.2% reduction in PSA. He went on to receive 2 more cycles of ⁶⁷Cu-SAR-bisPSMA and achieved undetectable PSA levels. In a follow-up bone scan and CT no metastatic disease was observed. This participant only exhibited mild (Grade 1) related AEs, most of which were gastrointestinal events, with no haematological or renal AEs observed. The participant reported having excellent quality of life following the treatment.

The interim data from this Phase II continues to confirm the favourable safety profile and promising efficacy seen in previous cohorts of the SECuRE trial^[1] and supports the continuation of the trial with the aim to progress to a registrational Phase III study.

Clarity's Executive Chairperson, Dr Alan Taylor, commented, "SAR-bisPSMA continues generating world-class data in both theranostic and diagnostic trials. The combination of the optimised dimer 'bis' structure with the benefits of copper isotopes, enabled by the proprietary sarcophagine technology, is proving to have created a product that is here to challenge the current treatment and diagnostic paradigms in radiopharmaceuticals.

"We have already seen a glimpse of the effects of ⁶⁷Cu-SAR-bisPSMA through our Dose Escalation cohorts with additional and similar data being generated in the Cohort Expansion phase, demonstrating once again excellent efficacy and safety results of ⁶⁷Cu-SAR-bisPSMA.

"All of the participants with evaluable data treated in the Phase II to date have shown declines in PSA, with the majority showing PSA decreases of more than 50% and mostly having only mild or moderate AEs. Most of these patients have been treated with more than 5 systemic treatment regiments and had bone metastasis prior to entering the SECuRE study. Although the number of participants with evaluable data to date is small, it is incredible to see yet another extraordinary case where a patient who had bone metastasis prior to entering the study achieved undetectable PSA following ⁶⁷Cu-SAR-bisPSMA treatment, with no disease observed by anatomical and molecular imaging at the last assessments. This participant only experienced mild, transient AEs, most being gastrointestinal, and has reported having excellent quality of life following the treatment.

"Importantly, the work we have undertaken during the Dose Escalation Phase is now continuing to provide a strong foundation for us as we look ahead at protocol development and dosing for our Phase III clinical trial and commercialisation. As the participant numbers continue to increase with the trial enrollment, we continue to see very promising responses over and over again, giving us more confidence about the future of this product and its potential for commercialisation in metastatic castration-resistant prostate cancer (mCRPC). With three Fast Track Designations for the SAR-bisPSMA product and positive interactions with the US Food and Drug Administration (FDA) to date, we are working towards bringing this agent to clinicians and their patients around the world through the entirety of the prostate cancer journey, from first diagnosis to late-stage disease. All of these indications, being imaging in pre-definitive therapy and biochemical recurrence, as well as therapy in mCRPC, are blockbuster markets individually for prostate-specific membrane antigen (PSMA) targeted products, with an estimated combined market value of approximately US$10-15 billion by 2030. We are committed to continuing the development of this product, aiming to bring improved diagnostic and treatment options for prostate cancer in various stages of their disease."

About the SECuRE trial

The SECuRE trial (NCT04868604)^[2] is a Phase I/IIa theranostic trial for identification and treatment of participants with PSMA-expressing mCRPC using ⁶⁴Cu/⁶⁷Cu-SAR-bisPSMA. ⁶⁴Cu-SAR-bisPSMA is used to visualise PSMA-expressing lesions and select candidates for subsequent ⁶⁷Cu-SAR-bisPSMA therapy. The trial is a multi-centre, single arm, dose escalation study with a cohort expansion involving approximately 54 participants in the US. The overall aim of the trial is to determine the safety and efficacy of ⁶⁷Cu-SAR-bisPSMA for the treatment of prostate cancer.

The SECuRE trial consists of the Dose Escalation (Phase I) and Cohort Expansion (Phase II) Phases. Based on the data from the Dose Escalation Phase, which demonstrated a favourable safety profile and efficacy of ⁶⁷Cu-SAR-bisPSMA, the SECuRE trial progressed to the Cohort Expansion (Phase II) at an 8 GBq dose level as per the SRC recommendation (up to 6 cycles per patient in total)^[3].

Cohort 2 of the Dose Escalation phase of the trial, where participants were dosed with 8 GBq of ⁶⁷Cu-SAR-bisPSMA, demonstrated a very low rate of related AEs while all three participants achieved PSA declines of 80% or more (PSA80)^[1]. The Dose Escalation Phase also showed high PSA response rates of the mCRPC in the pre-chemotherapy setting with a favourable safety profile: 92% of pre-chemotherapy participants (12/13) demonstrated PSA drops greater than 35%, PSA reductions greater than 50% were reached in 61.5% (8/13) of participants, and reductions of 80% or more were achieved in 46.2% (6/13) of participants^[1]. These results supported the progress of the trial to its Cohort Expansion Phase using 8 GBq multi-dose in participants who had not received chemotherapy in the mCRPC setting.

Recruitment is currently ongoing into the Cohort Expansion Phase which will include 24 participants. A subset of participants will be treated with the combination of 8 GBq of ⁶⁷Cu-SAR-bisPSMA with enzalutamide (androgen receptor pathway inhibitor [ARPI]), in line with the positive results from the Enza-p trial^[4] and previous discussions with and advice from key global medical experts in the field of prostate cancer, including the Company's Clinical Advisory Board members, Prof Louise Emmett and Prof Oliver Sartor, as well as the SRC.

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word "bis", which reflects a novel approach of connecting two PSMA-targeting agents to Clarity's proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or ⁶⁴Cu) for imaging and copper-67 (Cu-67 or ⁶⁷Cu) for therapy.

⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA are unregistered products. The safety and efficacy of ⁶⁷Cu-SAR-bisPSMA and ⁶⁴Cu-SAR-bisPSMA have not been assessed by health authorities such as the US FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide^[5]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the US and around 35,770 deaths from the disease^[6].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing TCTs based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact: